Researchers have repurposed cancer immunotherapy tools to identify regions of SARS-CoV-2 to target with a vaccine. They believe the use of this strategy could help develop a vaccine that provides long-term protection from COVID-19.
Browsing: Clinical > Vaccines
In this interview we speak to Jonathan Kurtis (Brown University, RI, USA) about the discovery of a parasite protein that provides new insights into how malaria regulates infection levels within its host, along with new possibilities for a broadly effective vaccine and a new class of antimalarial drugs.
The first human trial testing a potential COVID-19 vaccine has been successful, with initial results suggesting the vaccine is safe and capable of generating an immune response against SARS-CoV-2 in humans.
Researchers have demonstrated that two COVID-19 vaccine candidates can protect against COVID-19 in primates, with re-exposure triggering an immune response in rhesus macaques.
Researchers at the Korea Institute of Science and Technology (KIST) and Catholic University of Korea (CUK) have developed a vaccine platform against MERS coronavirus (MERS-CoV) that could be used to develop a vaccine for COVID-19.
The Anticancer Fund has created an open-access, online database called Covid19db, which shows the COVID-19 clinical trials currently taking place. The database has detected over 200 clinical trials across 35 countries, testing 102 different investigational drugs.
As a result of the the pandemic we face, life-and-death choices will be made and often, artificial intelligence and machine learning can be used to make objective and informed recommendations. This editorial explores the challenges faced by healthcare systems, and how AI and machine learning can improve decision-making.
A vaccine against MERS has shown promise in mouse models, potentially aiding the development of a vaccine against COVID-19.